1. Autoimmunity (inflammatory demyelinative polyradiculoneuropathies).
2. Vasculitis (connective tissue diseases).
3. Systemic illness (diabetes, uremia, sarcoidosis, myxedema, acromegaly).
4. Cancer (paraneoplastic neuropathy).
5. Infections (diphtheria, leprosy, lyme disease, AIDS, herpes zoster).
6. Dysproteinemia (myeloma,cryoglobulinemia).
7. Nutritional deficiencies and alcoholism.
8. Compression and trauma.
9. Toxic industrial agents and drugs.
10. Inherited neuropathies.
Arteriole in diabetic nerve
Vascular thickening of an endoneurial arteriole in diabetes.
The most common cause of neuropathy in clinical practice is diabetes. Peripheral neuropathy develops in more than half of long term diabetics and goes in tandem with other complications, such as retinopathy and nephropathy. Diabetes causes several types of neuropathy, which include chronic symmetrical polyneuropathy, proximal neuropathy (diabetic amyotrophy), mononeuropathies, and cranial radiculopathies. The most common is a symmetrical sensorimotor neuropathy which causes pain, sensory loss, weak or absent tendon reflexes and, to a lesser extent, weakness. The pathological findings in this diabetic polyneuropathy are axonal loss, axonal regeneration, and in some patients, demyelination. Small axons are affected more severely.A prominent finding in diabetic neuropathy is thickening of endoneurial arterioles due to increased deposition of basement membrane material, similar to changes that occur in brain arterioles and glomerular capillaries. The pathogenesis of diabetic neuropathies is poorly understood. Ischemia is probably an important factor. Nonenzymatic glycation of neural structures and other biochemical changes in diabetes probably play a role also.
These uncommon neuropathies are presumed to be immune disorders in which antibodies and activated T-lymphocytes, reacting with antigens present on peripheral nerves, elicit an inflammatory and macrophage reaction that destroys myelin and axons. The strongest evidence of a humoral immune reaction in these neuropathies is that plasma exchange results in significant clinical improvement. The participation of cellular immunity is underlined by the pesence of T-lymphocytes around blood vessels in affected nerves. The two main entities in this group are the Guillain-Barré syndrome and chronic inflammatory demyelinative neuropathy. An experimental model of demyelinative neuropathy, experimental allergic neuritis (EAN), can be produced by injecting animals with myelin and Freund adjuvant or purified peripheral myelin protein P2. EAN is a cell-mediated immune reaction.
GBS. Inflammation in peripheral nerve.
The Guillain-Barré Syndrome(GBS) is not a single disease entity. It includes several variants: Acute inflammatory demyelinative polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), and the Miller-Fisher syndrome (MFS). AIDP accounts for 90% of GBS. It is rare but represents a medical emergency in which prompt diagnosis may save lives. It begins with paresthesias in the toes and fingertips, followed by rapidly advancing weakness and areflexia. Weakness reaches a plateau within four weeks, after which recovery begins. Some cases are fulminant, evolving in one or two days. At the height of their disease, many patients are completely paralyzed and unable to breathe. Even with modern intensive care, approximately 5% of patients die from respiratory paralysis, cardiac arrest (probably due to autonomic dysfunction), sepsis, and other complications. Ten percent of those who recover have residual weakness. Though easy to diagnose in its classical form, GBS is often missed because of atypical clinical features which include ophthalmoplegia, ataxia, sensory loss, and dysautonomia. Plasma exchange (presumably removing the offending antibodies) and intravenous immunoglobulin are the treatments of choice. The two key laboratory abnormalities in GBS are decreased nerve conduction velocity or conduction block and elevated CSF protein with relatively few cells (albuminocytologic dissociation).
Peripheral nerves show perivenular mononuclear cells, demyelination (myelin proteins are the source of elevated CSF protein), and macrophages. Axonal damage, which accounts for the permanent deficits, is variable and may be severe. The pathology is most severe in spinal roots and plexuses and less pronounced in more distal nerves. In the phase of recovery, the nerve contains thin myelin sheaths, indicating myelin regeneration. AMAN shows axonal damage with little inflammation.
About 20% to 30% of GBS cases are preceded by an infection with Campylobacter Jejuni. This association is more established in AMAN. An equal number are preceded by Cytomegalovirus (CMV) infection. The rest are preceded by Mycoplasma and other infections, or vaccinations. The bacterial wall of C. jejuni contains GM1 ganglioside. Anti-ganglioside antibodies, generated in the course of the infection, cross-react with GM1 ganglioside present in the axonal membrane at the nodes of Ranvier and in paranodal myelin. This contact elicits inflammation that damages these structures. Anti-GM1 antibodies are found in the serum of GBS patients. GBS following CMV infections has anti-GM2 antibodies.
Chronic inflammatory demyelinative polyradiculoneuropathy (CIDP) follows a chronic or relapsing course over many months or years and may cause severe permanent disability. Nerve conduction studies show decreased conduction velocity, conduction block, and prolonged distal latencies and F waves. In the active phase of the disease, the CSF shows elevated protein without increased cells. Pathologically, peripheral nerves show demyelination, thin (incompletely regenerated) myelin, and hypertrophic changes due to recurrent attacks of demyelination with intervals of repair. In chronic cases, there is significant axonal loss. Inflammation is variable, sometimes absent. The pathology is most severe in proximal nerve segments and spinal roots and may not be full blown in the sural nerve biopsy. CIDP is thought to represent an autoimmune T-cell and antibody reaction against unknown myelin antigens. Its treatment consists of plasma exchange, intravenous immunoglobulin, and corticosteroids.
The GBS and CIDP are the counterparts of MS for the peripheral nervous system. They are important, because timely intervention with plasma exchange can prevent death in the GBS and severe permanent disability in CIDP. There are standardized criteria for their diagnosis, based on the clinical, CSF, nerve conduction, and biopsy findings.
The inherited neuropathies are rare as a group and include lysosomal storage diseases, peroxisomal disorders, mitochondrial disorders, familial amyloidoses, and other entities. Neuropathy, in these diseases, is a component of a systemic metabolic defect. The inherited neuropathies include also a group of diseases called hereditary motor and sensory neuropathies (HMSN), in which neuropathy is the main or only abnormality. There are many variants of HMSN caused by mutations of numerous genes. The most common entity in this group and the most common overall familial neuropathy is Charcot-Marie-Tooth disease (CMT). In some writings the name CMT is used to describe a specific phenotype of HMSN and in others to encompass the entire group of HMSN.
CMT is not a single entity but a group of inherited neuropathies that are divided into 3 subtypes, CMT1, CMT2, and X-linked CMT. CMT1 is the most common inherited peripheral neuropathy. It affects 1 in 2500 persons and is autosomal dominant. It causes weakness and atrophy of distal muscles, especially those innervated by the peroneal nerve ("stork leg"), pes cavus, and sensory loss. A subset of patients have sensory ataxia and tremor (Roussy-Levy syndrome). CMT1 begins in childhood or adolescence and progresses slowly, involving other nerves. It is compatible with a normal lifespan. Nerve conduction studies show decreased conduction velocity. The nerve biopsy in CMT1 shows demyelination, myelin regeneration (thin myelin), axonal loss, and onion bulbs. In longstanding cases there is gross thickening of nerves, hence the term hypetrophic neuropathy.
CMT1 is genetically diverse. Its most common form is due to duplication of a segment of chromosome 17 (17p11.2-p12) that contains the gene for a 22 kd peripheral myelin protein, PMP22. This protein probably also plays a role in Schwann cell differentiation. CMT1 patients have three copies of the normal gene and presumably produce 1.5 times as much PMP22 as normal people do. Other forms of CMT1 are caused by mutations of the PMP22 gene or mutations of the Myelin Protein Zero (MPZ) gene. CMT2, though clinically similar to CMT1, is an axonal neuropathy caused by mutations of numerous genes, including MFN2, which encodes a mitochondrial membrane protein. X-linked CMT is caused by mutation of a gap junction protein, connexin 32. A deletion of the PMP22 gene causes hereditary neuropathy with liability to pressure palsies.
Congenital hypomyelinating neuropathy
Congenital hypomyelinating neuropathy. The Schwann cell touches the axon but makes no myelin. There are rings of basement membrane.
Autosomal dominant and autosomal recessive mutations of PMP22, MPZ, and other genes cause Dejerine-Sottas neuropathy, a severe infantile demyelinative hypertrophic neuropathy associated with developmental delay and severe slowing of nerve conduction velocity. Congenital hypomyelinating neuropathy (CHN), caused by mutations of PMP22, MPZ, EGR2, and other genes is characterized by neonatal hypotonia, arthrogryposis, developmental delay, and absence of onion bulbs. Instead, CHN nerves have concentric rings of basement membrane. The molecular abnormalities of HMSN underline the importance of myelin proteins for the structural stability of myelin and show how diverse genetic abnormalities can cause a similar phenotype.
Familial amyloid neuropathy. Amyloid deposition in nerve. Sirius red stain.
Familial amyloid neuropathies(FAP) are a group of familial systemic amyloidoses with involvement of peripheral nerves. The most common FAP is caused by an autosomal dominant mutation of the transthyretin gene on 18q11. The mutant protein is deposited in the form of amyloid and damages peripheral nerves, the heart, kidneys, gastrointestinal tract, and other organs. In nerves, amyloid damages first and most severely small fibers, causing loss of pain and temperature sensation and autonomic dysfunction. Transthyretin is produced in the liver. Liver transplantation arrests the progression of the disease.
Myeloma and other monoclonal plasma cell proliferations result in the production of abnormal amounts of immunoglobulins and immunoglobulin chains. In some of these conditions, immunoglobulins form amyloid deposits which damage nerve fibers mechanically. In others, immunoglobulins have antibody activity against MBP and other myelin proteins and cause a demyelinative neuropathy. Other plasma cell dyscrasias and dysproteinemias cause vasculitis.
Churg-Strauss syndrome. Necrotizing arteritis and eosinophilia in a nerve biopsy.
Polyarteritis nodosa and other vasculitides often involve peripheral nerves causing single or multiple mononeuropathies (due to nerve ischemia), asymmetric polyneuropathy, and distal symmetric polyneuropathy. A sural nerve biopsy along with a muscle biopsy are the best tissues for establishing the diagnosis of vasculitis. The nerve biopsy is diagnostic in over half of patients with systemic vasculitis and clinical neuropathy, and the diagnostic yield increases with the addition of a muscle biopsy. Such biopsies show necrotizing arteritis, perivascular inflammatory infiltrates, hemorrhage and hemosiderin deposition, neovascularization in epineurial arteries, and variable changes in nerve fascicles, depending on the severity and stage of neuropathy. The muscle shows vasculitis and denervation atrophy.
- Lauria G, Lombardi R. Skin biopsy: a new tool for diagnosing peripheral neuropathy. BMJ 2007;334:1159-62 PubMed
- Szigeti K, Lupski JR. Charcot-Marie-Tooth disease. Eur J Hum Genet 2009;17:703-10. PubMed
- Gabreels-Festen A:Dejerine-Sottas syndrome grown to maturity: overview of genetic and morphological heterogeneity and follow up of 25 patients. J Anat 2002;200:341-56.PubMed
Updated: February, 2011